Shanghai Obio Technology (Group) Corp., Ltd. (SHA:688238)

China · Delayed Price · Currency is CNY

6.60

-0.19 (-2.80%)

At close: May 12, 2026

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017
Gene Therapy CRO Service						36.69M	36.09M	29.35M	-
Gene Therapy CRO Service Growth						1.67%	22.95%	-	-
Gene Therapy CDMO Service						101.71M	24.83M	12.91M	-
Gene Therapy CDMO Service Growth						309.64%	92.31%	-	-
Biological Agents, Reagents and Others						3.91M	1.93M	1.09M	-
Biological Agents, Reagents and Others Growth						102.97%	77.34%	-	-
Mechanism and Function Service						-	-	-	6.60M
CRO/CDMO/CMO Business						-	-	-	443.32K
Merchandise Sales and Others						-	-	-	2.56M
Pre-Made Virus Service						-	-	-	5.08M
Custom Virus Service						-	-	-	13.14M
Total						142.31M	62.84M	43.35M	27.83M
Total Growth						126.46%	44.98%	55.78%	-

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Eastern Region						72.37M	-	-	-	-
South China						35.75M	-	-	-	-
Northern Region						10.46M	-	-	-	-
Southwest						18.48M	-	-	-	-
Others						4.89M	-	-	-	-
Overseas						360.74K	-	-	-	-
China						-	-	-	-	20.16M
China Growth						-	-	-	-	46.12%
Total						142.31M	-	-	-	20.16M
Total Growth						-	-	-	-	46.12%

Source: S&P Global Market Intelligence.